QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2…